Windtree Therapeutics, Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Jed A. Latkin
- Full Time Employees
- 14
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 2600 Kelly Road Warrington PA United States of America 18976-3622
- IPO Date
- Aug 7, 1995
- CIK
- 0000946486
- Website
- windtreetx.com
- Similar Companies
- Business
- Windtree Therapeutics, Inc. (WINT) is a clinical-stage biotechnology company focused on developing therapies for acute cardiovascular disorders, respiratory diseases, and oncology indications. Founded in 1992 and headquartered in Warrington, Pennsylvania, the company offers a pipeline of product candidates including istaroxime, a first-in-class dual-mechanism therapy in Phase 2b trials for acute decompensated heart failure and early cardiogenic shock via SERCA2a activation and Na+/K+ ATPase inhibition; AEROSURF, an aerosolized KL4-surfactant in Phase 2b for respiratory distress syndrome in premature infants; Surfaxin, a KL4-surfactant for respiratory conditions; rostafuroxin in Phase 2b for genetically associated hypertension; and preclinical oral and intravenous SERCA2a activators for chronic and acute heart failure. It operates primarily in the United States with global licensing partnerships such as those with Lee’s Pharmaceutical Ltd., Philip Morris USA Inc., and Johnson & Johnson for surfactant technologies and aerosol delivery systems developed with Battelle Memorial Institute. In 2025, Windtree undergoes a major strategic transformation, with stockholders approving ten proposals in August including the establishment of a Windtree Environmental Services division through a transformational acquisition targeting the $85 billion U.S. market for revenue generation and profitability; an increase in authorized shares from 125 million to 1 billion to support growth and deals; abandonment of a prior cryptocurrency treasury strategy; and plans to partner cardiovascular and oncology assets to eliminate approximately $8.8 million in 2024 R&D expenses.
CommLoan Achieves Nationwide Regulatory Approval Across All 50 States
Windtree Therapeutics Announces It Will Receive $7.5 Million In Cash and Securities from the Recently Executed Termination Agreement with an Environmental Services Company
Windtree Therapeutics Announces It Will Receive $7.5 Million In Cash and Securities from the Recently Executed Termination Agreement with an Environmental Services Company
Windtree Therapeutics, Inc. (NASDAQ:WINT) Short Interest Update
Windtree Announces Istaroxime has been Chosen for a Plenary Session Presentation at the Heart Failure Society of America 2025
Windtree Therapeutics Announces Large Reduction of Preferred Series C and D Shares Outstanding by Conversion and Redemption
Windtree Therapeutics Announces Up To $520 Million in New Funding to Amplify BNB Cryptocurrency Treasury Strategy
Windtree To Launch BNB Crypto Treasury Strategy With Agreement For $60 Million Investment Led By Build And Build Corp. With Up To $140 Million More In Follow On Subscriptions
Windtree Announces Issuance of Istaroxime Patent for the United States for Acute Heart Failure
Windtree Advances Lower Cost Manufacturing of PHEXXI, Evofem's Hormone-Free, On-Demand Prescription Contraceptive Gel
Windtree Therapeutics Announces Istaroxime Cardiogenic Shock SCAI Stage C Phase 2 Study Planned Interim Analysis Results Targeted for July 2025
Windtree Therapeutics Announces Presentation of Preclinical Data on Istaroxime and a Selective SERCA2a Activator at the European Society of Cardiology Heart Failure Conference May 17, 2025
Windtree Announces Istaroxime Exclusivity and Intellectual Property Potential Strategy for US
Evofem Expects Significant Reduction in PHEXXI Manufacturing Cost Through Agreement with Windtree Therapeutics
Windtree Therapeutics Regains Compliance with Nasdaq Listing Rules
Windtree Announces License and Supply Agreement to Become Sourcing Partner for a Small Biotech with an FDA Approved Product
Windtree Strengthens Global Intellectual Property Portfolio with New Japanese Patent For the Company's Oncology Pipeline
WINT and Ferguson announce strategic collaboration to elevate water management and leak mitigation for real estate and construction
Windtree Announces the Addition of Leanne Kelly to Its Board of Directors
Windtree Announces New Istaroxime Patent Filing for Preventing or Reducing the Risk of Acute Myocardial Arrhythmia